Management of nontuberculous mycobacterial (NTM) lung disease

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 1, 2013, Pages 135-142

  Philley, Julie V ^a   Griffith, David E ^a  

^a Baylor UT Houston Center for AIDS Research   (United States)

Author keywords

Mycobacterium abscessus; Mycobacterium avium complex; nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AZITHROMYCIN; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; COLISTIN; DOXYCYCLINE; ETHAMBUTOL; IMIPENEM; RIFAMPICIN; STREPTOMYCIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; FIBROSING ALVEOLITIS; HUMAN; LUNG NODULE; LUNG RESECTION; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM ABSCESSUS; NEPHROTOXICITY; NUTRITIONAL STATUS; OTOTOXICITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG DISEASES; MEDICATION ADHERENCE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84874398806     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1333575     Document Type: Article

References (55)

1. Adjemian J., Olivier K. N., Seitz A. E., Holland S. M., Prevots D. R. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med: 2012; 185 8 881 886
2. Prevots D. R., Shaw P. A., Strickland D., et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med: 2010; 182 7 970 976
3. Winthrop K. L., McNelley E., Kendall B., et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med: 2010; 182 7 977 982
4. Griffith D. E., Aksamit T., Brown-Elliott B. A., et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med: 2007; 175 4 367 416 (dosage error corrected in Am J Respir Crit Care Med 2007;175(7):744-745)
5. Ray W. A., Murray K. T., Hall K., Arbogast P. G., Stein C. M. Azithromycin and the risk of cardiovascular death. N Engl J Med: 2012; 366 20 1881 1890
6. van Ingen J., Boeree M. J., van Soolingen D., Mouton J. W. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat: 2012; 15 3 149 161
7. Griffith D. E., Aksamit T. R. Bronchiectasis and nontuberculous mycobacterial disease. Clin Chest Med: 2012; 33 2 283 295
8. Corpe R. F. Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev Infect Dis: 1981; 3 5 1064 1067
9. Nelson K. G., Griffith D. E., Brown B. A., Wallace R. J. Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg: 1998; 66 2 325 330 (Pubitemid 28410654)
10. Shiraishi Y., Nakajima Y., Takasuna K., Hanaoka T., Katsuragi N., Konno H. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg: 2002; 21 2 314 318 (Pubitemid 34134489)
11. Mitchell J. D., Bishop A., Cafaro A., Weyant M. J., Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg: 2008; 85 6 1887 1892, discussion 1892-1893
12. Yu J. A., Pomerantz M., Bishop A., Weyant M. J., Mitchell J. D. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardiothorac Surg: 2011; 40 3 671 675
13. Griffith D. E., Girard W. M., Wallace R. J. Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis: 1993; 147 5 1271 1278 (Pubitemid 23149890)
14. Jeon K., Kwon O. J., Lee N. Y., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med: 2009; 180 9 896 902
15. Jarand J., Levin A., Zhang L., Huitt G., Mitchell J. D., Daley C. L. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis: 2011; 52 5 565 571
16. Feazel L. M., Baumgartner L. K., Peterson K. L., Frank D. N., Harris J. K., Pace N. R. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci U S A: 2009; 106 38 16393 16399
17. Nishiuchi Y., Maekura R., Kitada S., et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis: 2007; 45 3 347 351 (Pubitemid 47101032)
18. Falkinham J. O. III, Iseman M. D., de Haas P., van Soolingen D. Mycobacterium avium in a shower linked to pulmonary disease. J Water Health: 2008; 6 2 209 213 (Pubitemid 351972136)
19. Field S. K., Fisher D., Cowie R. L. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest: 2004; 126 2 566 581 (Pubitemid 39093445)
20. Wallace R. J. Jr, Brown B. A., Griffith D. E., et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med: 1994; 149 5 1335 1341 (Pubitemid 24147078)
21. Wallace R. J. Jr, Brown B. A., Griffith D. E., Girard W. M., Murphy D. T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med: 1996; 153 6 Pt 1 1766 1772 (Pubitemid 26187897)
22. Kobashi Y., Yoshida K., Miyashita N., Niki Y., Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother: 2006; 12 4 195 202 (Pubitemid 44327188)
23. Kobashi Y., Abe M., Mouri K., Obase Y., Miyashita N., Oka M. Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease. J Infect: 2010; Nov 19. [Epub ahead of print]
24. Kobashi Y., Abe M., Mouri K., Obase Y., Kato S., Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother: 2012; 18 4 436 443
25. Bates J. H. Mycobacterium avium disease: progress at last. Am J Respir Crit Care Med: 1996; 153 6 Pt 1 1737 1738
26. Griffith D. E., Brown B. A., Murphy D. T., Girard W. M., Couch L., Wallace R. J. Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis: 1998; 178 1 121 126 (Pubitemid 28328084)
27. Lam P. K., Griffith D. E., Aksamit T. R., et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med: 2006; 173 11 1283 1289 (Pubitemid 43848401)
28. van Ingen J., Egelund E. F., Levin A., et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med: 2012; Jun 28. [Epub ahead of print]
29. Kobashi Y., Matsushima T., Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med: 2007; 101 1 130 138 (Pubitemid 44835234)
30. Ramsey B. W., Pepe M. S., Quan J. M., et al. Cystic Fibrosis Inhaled Tobramycin Study Group Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med: 1999; 340 1 23 30 (Pubitemid 29024680)
31. Davis K. K., Kao P. N., Jacobs S. S., Ruoss S. J. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med: 2007; 7 2
32. Meier A., Heifets L., Wallace R. J. Jr., et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis: 1996; 174 2 354 360 (Pubitemid 26251422)
33. Griffith D. E., Brown-Elliott B. A., Langsjoen B., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med: 2006; 174 8 928 934 (Pubitemid 44564794)
34. McArdle J. R., Talwalkar J. S. Macrolides in cystic fibrosis. Clin Chest Med: 2007; 28 2 347 360 (Pubitemid 46654478)
35. Yates B., Murphy D. M., Forrest I. A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med: 2005; 172 6 772 775 (Pubitemid 41324235)
36. Poletti V., Casoni G., Chilosi M., Zompatori M. Diffuse panbronchiolitis. Eur Respir J: 2006; 28 4 862 871 (Pubitemid 46332008)
37. Piacentini G. L., Peroni D. G., Bodini A., et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc: 2007; 28 2 194 198
38. Albert R. K., Connett J., Bailey W. C., et al. COPD Clinical Research Network Azithromycin for prevention of exacerbations of COPD. N Engl J Med: 2011; 365 8 689 698
39. Renna M., Schaffner C., Brown K., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest: 2011; 121 9 3554 3563
40. Kohno Y., Ohno H., Miyazaki Y., et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother: 2007; 51 11 4071 4076 (Pubitemid 350057806)
41. Jenkins P. A., Campbell I. A., Banks J., Gelder C. M., Prescott R. J., Smith A. P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax: 2008; 63 7 627 634 (Pubitemid 351969257)
42. Field S. K., Cowie R. L. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest: 2003; 124 4 1482 1486 (Pubitemid 37290061)
43. Chaisson R. E., Keiser P., Pierce M., et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS: 1997; 11 3 311 317 (Pubitemid 27086970)
44. Wallace R. J. Jr, Zhang Y., Brown-Elliott B. A., et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis: 2002; 186 2 266 273 (Pubitemid 34765517)
45. van Ingen J., Boeree M. J., de Lange W. C., de Haas P. E., Dekhuijzen P. N., van Soolingen D. Clinical relevance of Mycobacterium szulgai in the Netherlands. Clin Infect Dis: 2008; 46 8 1200 1205 (Pubitemid 351589903)
46. van Ingen J., Boeree M. J., Dekhuijzen P. N., van Soolingen D. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J: 2008; 31 1 106 109
47. van Ingen J., Totten S. E., Heifets L. B., Boeree M. J., Daley C. L. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents: 2012; 39 2 173 176
48. Hoefsloot W., Boeree M. J., van Ingen J., et al. The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis: 2008; 12 9 987 993
49. Hoefsloot W., van Ingen J., de Lange W. C., Dekhuijzen P. N., Boeree M. J., van Soolingen D. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J: 2009; 34 4 926 931
50. van Ingen J., Boeree M. J., de Lange W. C., et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis: 2008; 14 3 385 389 (Pubitemid 351451384)
51. Andréjak C., Lescure F. X., Pukenyte E., et al. Xenopi Group Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax: 2009; 64 4 291 296
52. Nash K. A., Brown-Elliott B. A., Wallace R. J. Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother: 2009; 53 4 1367 1376
53. Koh W. J., Jeon K., Lee N. Y., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med: 2011; 183 3 405 410
54. Leao S. C., Tortoli E., Euzéby J. P., Garcia M. J. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol: 2011; 61 Pt 9 2311 2313
55. Lyu J., Jang H. J., Song J. W., et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med: 2011; 105 5 781 787